Academia
On this page, you will find information on the European Medicines Agency’s (EMA) activities that are most relevant to academia, including news and events. Learn more about the Agency's resources to support medicine development:
Human regulatory: Research and development
Veterinary regulatory: Research and development
Learn more about how EMA interacts with academia.
Featured information
-
List item
COVID-19 vaccines: social media campaign
Follow our social media campaign on COVID-19 vaccines on Twitter and LinkedIn, using the hashtags #VaccinesWork and #COVID-19vaccines. We are focusing on EMA’s role in the accelerated development, evaluation and safety-monitoring of COVID-19 vaccines. We encourage you to share and comment on our posts, or to share your own posts using the hashtags.
-
List item
EMA celebrates 15 years supporting SMEs in the EU
EMA’s recent roundtable with SME stakeholders and latest SME survey results highlight the key achievements of the SME Regulation and the challenges and opportunities for EU support to SMEs in the pharmaceutical sector.
-
List item
Public meeting on COVID-19 vaccines
EMA held a public meeting on 11 December 2020 to explain the regulatory processes in the EU for the development, evaluation, approval and safety monitoring of COVID-19 vaccines, and to hear fom the public and other stakeholder groups on their needs, expectations and concerns. The video recording of the meeting and the presentations are available.
-
List item
European medicines agencies network strategy to 2025
The strategy sets out how the network will continue to enable the supply of safe and effective medicines, in the face of developments in science, medicine, digital technologies, globalisation and emerging health threats, such as the COVID-19 pandemic.
-
List item
Paediatric medicines: progress on action plan
A progress update is available on the EMA / European Commission action plan for supporting the development of medicines for children. It specifies the status of each action and outlines concrete achievements to December 2020.
-
List item
Fee waiver for protocol assistance (scientific advice for orphan medicines)
Applicants from the academic sector can receive free protocol assistance for developing orphan medicines.
-
List item
Coronavirus disease (COVID-19)
Keep up to date with the latest information on how EMA is handling the COVID-19 pandemic.
-
List item
Supporting medicine developers
EMA's infosheet highlights the regulatory tools EMA offers to support the development of new and innovative medicines – from the early phases in the laboratory all the way to the patient.
-
List item
